Business
Vera Therapeutics Announces Two Oral Presentations at the 59th European Renal Association – European Dialysis and Transplant Association Congress Featuring New Clinical Data on Atacicept in IgA Nephropathy and in Systemic Lupus Erythematosus
BRISBANE, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and
About this update from Vera Therapeutics, Inc.
[{"type":"text","content":"BRISBANE, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, today announced two oral presentations featuring new clinical data on the Company’s lead product candidate, atacicept, to be presented at the 59th European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Congress being held May 19-22, 2022 in Paris, France, in person and virtually, at the Paris Expo Porte de Versailles. The oral presentations include new clinical data from the Phase 2a JANUS clinical trial of atacicept in patients with IgA nephropathy (IgAN) and first-time renal data from a post-hoc analysis of the Phase 2 APRIL-SLE study evaluating atacicept in patients with systemic lupus erythematosus (SLE). Details of the oral presentations are as follows: Title:Atacicept Reduces Serum Anti-Gd-IgA1 Levels in Patients with Immunoglobulin A Nephropathy (IgAN)Date:May 20, 2022, 3:00-4:30 PM CEST / 9:00-10:30AM ETSession:Recent Advances in the Treatment of IgAN (FC14)Presentation Number:FC051Location:Hall S03Presenter:Jonathan Barratt, PhD, FRCP, The Mayer Professor of Renal Medicine, University of Leicester, UK Title:Effect of Atacicept on Renal Function in Patients With Systemic Lupus Erythematosus (SLE)Date:May 20, 2022, 5:00-6:30 PM CEST / 11:00AM-12:30PM ETSession:New Advances in Lupus Nephropathy (S 3.3)Presentation Number:FC055Location:Hall N02Presenter:David Isenberg, M.D., ARC Diamond Jubilee Professor and director of the Centre for Rheumatology and Bloomsbury Rheumatology Unit, University College London, UK About AtaciceptAtacicept is an investigational recombinant fusion protein self-administered as a subcutaneous injection once weekly that contains the soluble transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI) receptor that binds to the cytokines B lymphocyte stimulator (BlyS) and a proliferation-inducing ligand (APRIL). These cytokines are members of the tumor necrosis factor family that promote B-cell survival and autoantibody production associated with certain autoimmune diseases, including IgA nephropathy (IgAN) and lupus nephritis. Atacicept showed a dose-dependent effect on key biomarkers and clinical markers in ...